Beta Bionics, developer of an automated insulin delivery system, has recently filed for an initial public offering. The company has not disclosed the number of shares it will offer or the price range. Beta Bionics plans for its shares to be listed on the Nasdaq under the ticker symbol “BBNX.”
The Irvine, California-based company makes an insulin pump called the iLet Bionic Pancreas, which was cleared by the Food and Drug Administration in 2023. Beta Bionics plans to use the proceeds to grow its sales and manufacturing infrastructure and develop new features for its device.
To find out more, CLICK HERE.
